REMOLD-MM
A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myeloma-related OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 10 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Tags
- Sclerostin
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1461
- NCT Identifier
- NCT05775094
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.